{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:47:10Z","timestamp":1789994830429,"version":"4.0.1"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T00:00:00Z","timestamp":1496793600000},"content-version":"am","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003357","name":"Gebert R\u00fcf Foundation","doi-asserted-by":"publisher","award":["GRS-041\/11"],"award-info":[{"award-number":["GRS-041\/11"]}],"id":[{"id":"10.13039\/501100003357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["310030_135732"],"award-info":[{"award-number":["310030_135732"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007103","name":"Swiss Chemical Industry (SSCI)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007103","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.addr.2016.01.010","type":"journal-article","created":{"date-parts":[[2016,1,27]],"date-time":"2016-01-27T18:51:22Z","timestamp":1453920682000},"page":"108-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":325,"special_numbering":"C","title":["Oral delivery of macromolecular drugs: Where we are after almost 100 years of attempts"],"prefix":"10.1016","volume":"101","author":[{"given":"Elena","family":"Moroz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Matoori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Leroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2016.01.010_bb0005","first-page":"651","article-title":"Insulin in hospital and home","volume":"2","author":"Joslin","year":"1922","journal-title":"J. Metab. Res."},{"key":"10.1016\/j.addr.2016.01.010_bb0010","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.biotechadv.2014.07.006","article-title":"A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules","volume":"32","author":"Choonara","year":"2014","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.addr.2016.01.010_bb0015","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1517\/17425247.2014.945420","article-title":"Advances in oral macromolecular drug delivery","volume":"11","author":"Hwang","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2016.01.010_bb0020","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s11095-013-1233-y","article-title":"Improving the stability and activity of oral therapeutic enzymes-recent advances and perspectives","volume":"31","author":"Fuhrmann","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2016.01.010_bb0025","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrd1067","article-title":"Challenges for the oral delivery of macromolecules","volume":"2","author":"Goldberg","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2016.01.010_bb0030","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/mi.2010.5","article-title":"Multiple facets of intestinal permeability and epithelial handling of dietary antigens","volume":"3","author":"M\u00e9nard","year":"2010","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.addr.2016.01.010_bb0035","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.addr.2013.01.002","article-title":"Targeted nanoparticles with novel non-peptidic ligands for oral delivery","volume":"65","author":"Rieux","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2016.01.010_bb0040","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.addr.2003.10.018","article-title":"M cell targeting by lectins: a strategy for mucosal vaccination and drug delivery","volume":"56","author":"Jepson","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2016.01.010_bb0045","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0966-842X(98)01337-7","article-title":"Studying M cells and their role in infection","volume":"6","author":"Jepson","year":"1998","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.addr.2016.01.010_bb0050","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.ddtec.2011.11.006","article-title":"Overcoming poor permeability: translating permeation enhancers for oral peptide delivery","volume":"9","author":"Maher","year":"2012","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.addr.2016.01.010_bb0055","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/jps.21084","article-title":"Oral delivery of antisense oligonucleotides in man","volume":"97","author":"Tillman","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2016.01.010_bb0060","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.chembiol.2014.08.013","article-title":"Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates","volume":"21","author":"Doak","year":"2014","journal-title":"Chem. Biol."},{"key":"10.1016\/j.addr.2016.01.010_bb0065","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s13238-015-0164-2","article-title":"Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies","volume":"6","author":"Wang","year":"2015","journal-title":"Protein Cell"},{"key":"10.1016\/j.addr.2016.01.010_bb0070","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1080\/21645515.2015.1011019","article-title":"Vaccines for viral and bacterial pathogens causing acute gastroenteritis: part I: overview, vaccines for enteric viruses and Vibrio cholerae","volume":"11","author":"O'Ryan","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.addr.2016.01.010_bb0075","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/21645515.2015.1011578","article-title":"Vaccines for viral and bacterial pathogens causing acute gastroenteritis: part II: vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni","volume":"11","author":"O'Ryan","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.addr.2016.01.010_bb0080","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nri3251","article-title":"Recent progress in mucosal vaccine development: potential and limitations","volume":"12","author":"Lycke","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2016.01.010_bb0085","doi-asserted-by":"crossref","DOI":"10.3109\/07388551.2014.992388","article-title":"Targeted localized use of therapeutic antibodies: a review of non-systemic, topical and oral applications","author":"Jones","year":"2015","journal-title":"Crit. Rev. Biotechnol."},{"key":"10.1016\/j.addr.2016.01.010_bb0090","doi-asserted-by":"crossref","first-page":"6724","DOI":"10.4049\/jimmunol.0902374","article-title":"Complement activation by CpG in a human whole blood loop system: mechanisms and immunomodulatory effects","volume":"183","author":"Mangsbo","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2016.01.010_bb0095","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jconrel.2014.09.031","article-title":"Targeting of gastrointestinal tract for amended delivery of protein\/peptide therapeutics: strategies and industrial perspectives","volume":"196","author":"Pawar","year":"2014","journal-title":"J. Control. Release"},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2016.01.010_bb0100","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1086\/491709","article-title":"Vancomycin: a history","volume":"42","author":"Levine","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2016.01.010_bb0105","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1074-5521(98)90060-6","article-title":"Sequencing and analysis of genes involved in the biosynthesis of a vancomycin group antibiotic","volume":"5","author":"van Wageningen","year":"1998","journal-title":"Chem. Biol."},{"key":"10.1016\/j.addr.2016.01.010_bb0110","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1038\/1841894b0","article-title":"Selective inhibition of ribonucleic acid synthesis in Staphylococcus aureus by vancomycin","volume":"184","author":"Jordan","year":"1959","journal-title":"Nature"},{"key":"10.1016\/j.addr.2016.01.010_bb0115","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-015-0772-5","article-title":"Propofol, midazolam, vancomycin and cyclosporine therapeutic drug monitoring in extracorporeal membrane oxygenation circuits primed with whole human blood","volume":"19","author":"Lemaitre","year":"2015","journal-title":"Crit. Care."},{"key":"10.1016\/j.addr.2016.01.010_bb0120","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3109\/00365548.2010.544671","article-title":"Systemic absorption of oral vancomycin in patients with Clostridium difficile infection","volume":"43","author":"Rao","year":"2011","journal-title":"Scand. J. Infect. dis."},{"key":"10.1016\/j.addr.2016.01.010_bb0125","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/2040622313511285","article-title":"Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance","volume":"5","author":"Mullane","year":"2014","journal-title":"Ther. Adv. Chronic Dis."},{"key":"10.1016\/j.addr.2016.01.010_bb0130","doi-asserted-by":"crossref","first-page":"5164","DOI":"10.1021\/jm5016846","article-title":"Clostridium difficile drug pipeline: challenges in discovery and development of new agents","volume":"58","author":"Jarrad","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2016.01.010_bb0135","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.drudis.2014.12.003","article-title":"Investigational new treatments for clostridium difficile infection","volume":"20","author":"Ivarsson","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.addr.2016.01.010_bb0140","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.lfs.2010.03.015","article-title":"Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract","volume":"86","author":"Bryant","year":"2010","journal-title":"Life Sci."},{"key":"10.1016\/j.addr.2016.01.010_bb0145","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ejphar.2010.09.019","article-title":"Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit","volume":"649","author":"Busby","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.addr.2016.01.010_bb0150","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2013.08.017","article-title":"Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3\u2032,5\u2032-monophosphate","volume":"145","author":"Castro","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2016.01.010_bb0155","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/apt.12604","article-title":"Review article: linaclotide for the management of irritable bowel syndrome with constipation","volume":"39","author":"Layer","year":"2014","journal-title":"Aliment. Pharm. Ther."},{"key":"10.1016\/j.addr.2016.01.010_bb0160","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1124\/jpet.112.199430","article-title":"Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation","volume":"344","author":"Busby","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.addr.2016.01.010_bb0165","first-page":"3777","article-title":"In vivo imaging of human colorectal cancer using radiolabeled analogs of the uroguanylin peptide hormone","volume":"29","author":"Liu","year":"2009","journal-title":"Anticancer Res."},{"key":"10.1016\/j.addr.2016.01.010_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(13)60585-5","article-title":"925g Plecanatide, a novel guanylate cyclase-C (GC-C) receptor agonist, is efficacious and safe in patients with chronic idiopathic constipation (CIC): results from a 951 patient, 12 week, multi-center trial","volume":"144","author":"Miner","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2016.01.010_bb0175","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1097\/00054725-201212001-00231","article-title":"SP-333, a guanylate cyclase C agonist, ameliorates DSS-colitis in mice via a novel cyclic GMP-mediated mechanism: P-198","volume":"18","author":"Shailubhai","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.addr.2016.01.010_bb0180","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2036.2012.05057.x","article-title":"Systematic review: antibodies and anti-TNF-\u03b1 levels in inflammatory bowel disease","volume":"35","author":"Chaparro","year":"2012","journal-title":"Aliment. Pharm. Ther."},{"key":"10.1016\/j.addr.2016.01.010_bb0185","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2174\/138945010790309867","article-title":"Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD?","volume":"11","author":"Lakatos","year":"2010","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.addr.2016.01.010_bb0190","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/ajg.2013.138","article-title":"Opportunistic infections with anti-tumor necrosis factor-\u03b1 therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials","volume":"108","author":"Ford","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.addr.2016.01.010_bb0195","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1097\/MIB.0b013e3182a11958","article-title":"AVX-470: a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease","volume":"19","author":"Bhol","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.addr.2016.01.010_bb0200","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3390\/nu3040442","article-title":"Perspectives on immunoglobulins in colostrum and milk","volume":"3","author":"Hurley","year":"2011","journal-title":"Nutrients"},{"key":"10.1016\/j.addr.2016.01.010_bb0205","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1128\/AAC.41.2.236","article-title":"Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract","volume":"41","author":"Kelly","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2016.01.010_bb0210","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/gut.44.2.212","article-title":"Bovine immunoglobulin concentrate-clostridium difficile retains C. difficile toxin neutralising activity after passage through the human stomach and small intestine","volume":"44","author":"Warny","year":"1999","journal-title":"Gut"},{"key":"10.1016\/j.addr.2016.01.010_bb0215","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/mi.2009.116","article-title":"Orally administered L. lactis secreting an anti-TNF nanobody demonstrate efficacy in chronic colitis","volume":"3","author":"Vandenbroucke","year":"2010","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.addr.2016.01.010_bb0220","doi-asserted-by":"crossref","first-page":"P104","DOI":"10.1186\/2045-7022-1-S1-P104","article-title":"Novel formulation of neutral lactase improves digestion of dairy products in case of lactose intolerance","volume":"1","author":"Fraissl","year":"2011","journal-title":"Clin. Transl. Allergy."},{"key":"10.1016\/j.addr.2016.01.010_bb0225","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3748\/wjg.v12.i2.187","article-title":"Management and treatment of lactose malabsorption","volume":"12","author":"Montalto","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.addr.2016.01.010_bb0230","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s11095-012-0951-x","article-title":"Celiac disease: a challenging disease for pharmaceutical scientists","volume":"30","author":"Matoori","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2016.01.010_bb0235","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nchem.1675","article-title":"Sustained gastrointestinal activity of dendronized polymer-enzyme conjugates","volume":"5","author":"Fuhrmann","year":"2013","journal-title":"Nat. Chem."},{"key":"10.1016\/j.addr.2016.01.010_bb0240","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0140-6736(80)90944-7","article-title":"Enzymatic control of phenylalanine intake in phenylketonuria","volume":"1","author":"Hoskins","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2016.01.010_bb0245","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/bit.20643","article-title":"Fermentation, purification, formulation, and pharmacological evaluation of a prolyl endopeptidase from Myxococcus xanthus: implications for celiac sprue therapy","volume":"92","author":"Gass","year":"2005","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.addr.2016.01.010_bb0250","article-title":"Site-specific polymer conjugation stabilizes therapeutic enzymes in the gastrointestinal tract","author":"Schulz","year":"2015","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2016.01.010_bb0255","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1002\/cncr.28365","article-title":"Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy","volume":"119","author":"Limaye","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2016.01.010_bb0260","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.oraloncology.2010.04.008","article-title":"AG013, a mouth rinse formulation of Lactococcus lactis secreting human trefoil factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis","volume":"46","author":"Caluwaerts","year":"2010","journal-title":"Oral Oncol."},{"key":"10.1016\/j.addr.2016.01.010_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(10)60041-8","article-title":"46 A phase 2a randomized placebo-controlled double-blind multi-center dose escalation study to evaluate the safety, tolerability, pharmacodynamics and efficacy of AG011 in patients with moderately active ulcerative colitis","volume":"138","author":"Vermeire","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2016.01.010_bb0270","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/ajg.2014.48","article-title":"Novel role of the serine protease inhibitor elafin in gluten-related disorders","volume":"109","author":"Galipeau","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.addr.2016.01.010_bb0275","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ejpb.2013.03.021","article-title":"Is there a future for cell-penetrating peptides in oligonucleotide delivery?","volume":"85","author":"Lee","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2016.01.010_bb0280","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.addr.2012.11.003","article-title":"Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tract","volume":"65","author":"Kriegel","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2016.01.010_bb0285","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.drudis.2011.01.003","article-title":"Intestinal delivery of non-viral gene therapeutics: physiological barriers and preclinical models","volume":"16","author":"O'Neill","year":"2011","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.addr.2016.01.010_bb0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115950","article-title":"Non-enzymatic depurination of nucleic acids: factors and mechanisms","volume":"9","author":"An","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2016.01.010_bb0295","doi-asserted-by":"crossref","first-page":"7350","DOI":"10.1073\/pnas.78.12.7350","article-title":"A DNA fragment with an alpha-phosphorothioate nucleotide at one end is asymmetrically blocked from digestion by exonuclease III and can be replicated in vivo","volume":"78","author":"Putney","year":"1981","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2016.01.010_bb0300","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.chembiol.2012.07.011","article-title":"Designing chemically modified oligonucleotides for targeted gene silencing","volume":"19","author":"Deleavey","year":"2012","journal-title":"Chem. Biol."},{"key":"10.1016\/j.addr.2016.01.010_bb0305","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1407250","article-title":"Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease","volume":"372","author":"Monteleone","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2016.01.010_bb0310","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/mt.2011.290","article-title":"Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease","volume":"20","author":"Monteleone","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2016.01.010_bb0315","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/apt.12369","article-title":"Meta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis","volume":"38","author":"Vegter","year":"2013","journal-title":"Aliment. Pharm. Ther."},{"key":"10.1016\/j.addr.2016.01.010_bb0320","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2036.2004.01863.x","article-title":"An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis","volume":"19","author":"Miner","year":"2004","journal-title":"Aliment. Pharm. Ther."},{"key":"10.1016\/j.addr.2016.01.010_bb0325","first-page":"2213","article-title":"Alteration of beta-catenin expression in colonic epithelial cells of familial adenomatous polyposis patients","volume":"56","author":"Inomata","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2016.01.010_bb0330","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.1158\/1538-7445.AM2012-5706","article-title":"Engineering of trans kingdom RNAi (tkRNAi) against gastrointestinal polyps","volume":"72","author":"Vaze","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2016.01.010_bb0335","doi-asserted-by":"crossref","first-page":"12868","DOI":"10.1021\/ja507547w","article-title":"Activatable cell penetrating peptide\u2013peptide nucleic acid conjugate via reduction of azobenzene PEG chains","volume":"136","author":"Lee","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2016.01.010_bb0340","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1021\/mp500809f","article-title":"Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs","volume":"12","author":"Wang","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2016.01.010_bb0345","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1107\/S0907444994006104","article-title":"Structure of octreotide, a somatostatin analogue","volume":"51","author":"Pohl","year":"1995","journal-title":"Acta Crystallogr. D."},{"key":"10.1016\/j.addr.2016.01.010_bb0350","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/1520-6017(200007)89:7<951::AID-JPS13>3.0.CO;2-1","article-title":"Intestinal absorption of octreotide: N-trimethyl chitosan chloride (TMC) ameliorates the permeability and absorption properties of the somatostatin analogue in vitro and in vivo","volume":"89","author":"Thanou","year":"2000","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2016.01.010_bb0355","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF00544562","article-title":"Absorption of an aqueous solution of a new synthetic somatostatin analogue administered to man by gavage","volume":"33","author":"K\u00f6hler","year":"1987","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2016.01.010_bb0360","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1007\/s11095-014-1303-9","article-title":"A novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms","volume":"31","author":"Tuvia","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2016.01.010_bb0365","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1210\/jc.2012-1179","article-title":"Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression","volume":"97","author":"Tuvia","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.addr.2016.01.010_bb0370","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1210\/jc.2014-4113","article-title":"Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial","volume":"100","author":"Melmed","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.addr.2016.01.010_bb0375","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJM197603042941001","article-title":"DDAVP in the treatment of central diabetes insipidus","volume":"294","author":"Robinson","year":"1976","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2016.01.010_bb0380","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0378-5173(90)90267-8","article-title":"Absorption of a vasopressin analogue, 1-deamino-8-d-arginine-vasopressin (dDAVP), in a human intestinal epithelial cell line, CaCO-2","volume":"64","author":"Lundin","year":"1990","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2016.01.010_bb0385","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2265.1993.tb00990.x","article-title":"Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers","volume":"38","author":"Fjellestad-Paulsen","year":"1993","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.addr.2016.01.010_bb0390","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1177\/0091270006291838","article-title":"Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults","volume":"46","author":"Osterberg","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2016.01.010_bb0395","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1365-2265.1998.00340.x","article-title":"Effect of food intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (DDAVP) in hydrated normal subjects","volume":"48","author":"Rittig","year":"1998","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.addr.2016.01.010_bb0400","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.juro.2007.03.015","article-title":"The comparative safety of oral versus intranasal desmopressin for the treatment of children with nocturnal enuresis","volume":"178","author":"Robson","year":"2007","journal-title":"J. Urol."},{"key":"10.1016\/j.addr.2016.01.010_bb0405","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/j.1476-5381.1996.tb15612.x","article-title":"Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation","volume":"118","author":"Fricker","year":"1996","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.addr.2016.01.010_bb0410","doi-asserted-by":"crossref","first-page":"12125","DOI":"10.1021\/ja303200d","article-title":"Intestinal permeability of cyclic peptides: common key backbone motifs identified","volume":"134","author":"Beck","year":"2012","journal-title":"J. Am. Chem. Soc."},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2016.01.010_bb0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-4362.36.s1.2.x","article-title":"Bioavailability and pharmacokinetics of cyclosporine formulations: neoral vs sandimmune","volume":"36","author":"Choc","year":"1997","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.addr.2016.01.010_bb0420","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/jps.2600830336","article-title":"Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation","volume":"83","author":"Kovarik","year":"1994","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2016.01.010_bb0425","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1023\/A:1018922517162","article-title":"Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation","volume":"11","author":"Mueller","year":"1994","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2016.01.010_bb0430","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1021\/jm00014a017","article-title":"Gonadotropin-releasing hormone antagonists: novel members of the azaline B family","volume":"38","author":"Rivier","year":"1995","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2016.01.010_bb0435","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1517\/17425247.3.5.685","article-title":"Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET","volume":"3","author":"Leonard","year":"2006","journal-title":"Expert Opin. Drug Del."},{"key":"10.1016\/j.addr.2016.01.010_bb0440","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00280-009-1038-1","article-title":"Oral administration of the GnRH antagonist acyline, in a GIPET-enhanced tablet form, acutely suppresses serum testosterone in normal men: single-dose pharmacokinetics and pharmacodynamics","volume":"64","author":"Amory","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.addr.2016.01.010_bb0445","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00198-007-0490-1","article-title":"Salmon calcitonin: a review of current and future therapeutic indications","volume":"19","author":"Chesnut","year":"2008","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.addr.2016.01.010_bb0450","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.ejps.2013.01.009","article-title":"Colonic absorption of salmon calcitonin using tetradecyl maltoside (TDM) as a permeation enhancer","volume":"48","author":"Petersen","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2016.01.010_bb0455","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6904-8-5","article-title":"Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of Salmon Calcitonin","volume":"8","author":"Karsdal","year":"2008","journal-title":"BMC Clin. Pharmacol."},{"key":"10.1016\/j.addr.2016.01.010_bb0460","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.joca.2009.08.004","article-title":"The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study","volume":"18","author":"Karsdal","year":"2010","journal-title":"Osteoarthr. Cartil."},{"key":"10.1016\/j.addr.2016.01.010_bb0465","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/jbmr.1602","article-title":"A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial","volume":"27","author":"Binkley","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.addr.2016.01.010_bb0470","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ejpb.2013.12.017","article-title":"The role of citric acid in oral peptide and protein formulations: relationship between calcium chelation and proteolysis inhibition","volume":"86","author":"Welling","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2016.01.010_bb0475","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1007\/s00198-014-2796-0","article-title":"Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial","volume":"25","author":"Binkley","year":"2014","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.addr.2016.01.010_bb0480","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1111\/jgs.13167","article-title":"Cancer risk associated with calcitonin use","volume":"62","author":"Lempicki","year":"2014","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.addr.2016.01.010_bb0485","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1016\/j.bmcl.2013.05.022","article-title":"Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity","volume":"23","author":"Lorenz","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.addr.2016.01.010_bb0490","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1177\/193229680900300323","article-title":"Oral insulin and buccal insulin: a critical reappraisal","volume":"3","author":"Heinemann","year":"2009","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2016.01.010_bb0495","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1177\/1932296814529988","article-title":"Oral insulin reloaded: a structured approach","volume":"8","author":"Zijlstra","year":"2014","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2016.01.010_bb0500","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/193229681300700228","article-title":"Oral insulin delivery: how far are we?","volume":"7","author":"Fonte","year":"2013","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2016.01.010_bb0505","doi-asserted-by":"crossref","first-page":"313","DOI":"10.4155\/ppa.14.15","article-title":"Formulation strategies to improve oral peptide delivery","volume":"3","author":"Maher","year":"2014","journal-title":"Pharm. Pat. Anal."},{"key":"10.1016\/j.addr.2016.01.010_bb0510","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1463-1326.2009.01146.x","article-title":"The glucose lowering effect of an oral insulin (capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes","volume":"12","author":"Luzio","year":"2010","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.addr.2016.01.010_bb0515","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1463-1326.2009.01153.x","article-title":"Open-label study to assess the safety and pharmacodynamics of five oral insulin formulations in healthy subjects","volume":"12","author":"Eldor","year":"2010","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.addr.2016.01.010_bb0520","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059524","article-title":"Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study","volume":"8","author":"Eldor","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2016.01.010_bb0525","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1464-5491.2004.01160.x","article-title":"A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects","volume":"21","author":"Kidron","year":"2004","journal-title":"Diabet. Med."},{"key":"10.1016\/j.addr.2016.01.010_bb0530","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1002\/btpr.487","article-title":"Development of a process to manufacture PEGylated orally bioavailable insulin","volume":"26","author":"Hazra","year":"2010","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.addr.2016.01.010_bb0535","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00449-012-0722-4","article-title":"A novel one-pot de-blocking and conjugation reaction step leads to process intensification in the manufacture of PEGylated insulin IN-105","volume":"35","author":"Hazra","year":"2012","journal-title":"Bioprocess Biosyst. Eng."},{"key":"10.1016\/j.addr.2016.01.010_bb0540","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1463-1326.2010.01213.x","article-title":"A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects","volume":"12","author":"Khedkar","year":"2010","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.addr.2016.01.010_bb0545","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1177\/193229680900300627","article-title":"Hepatic-directed vesicle insulin: a review of formulation development and preclinical evaluation","volume":"3","author":"Geho","year":"2009","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2016.01.010_bb0550","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/1932296814524871","article-title":"A single-blind, placebo-controlled, dose-ranging trial of oral hepatic-directed vesicle insulin add-on to oral antidiabetic treatment in patients with type 2 diabetes mellitus","volume":"8","author":"Geho","year":"2014","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2016.01.010_bb0555","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1517\/17425247.5.9.1047","article-title":"Delivery of insulin to the buccal mucosa utilizing the RapidMist system","volume":"5","author":"Bernstein","year":"2008","journal-title":"Expert Opin. Drug Del."},{"key":"10.1016\/j.addr.2016.01.010_bb0560","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1463-1326.2010.01312.x","article-title":"Buccal spray insulin in subjects with impaired glucose tolerance: the prevoral study","volume":"13","author":"Palermo","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.addr.2016.01.010_bb0565","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/oli.1.2000.10.35","article-title":"Absorption of antisense oligonucleotides in rat intestine: effect of chemistry and length","volume":"10","author":"Khatsenko","year":"2000","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"10.1016\/j.addr.2016.01.010_bb0570","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/14712598.2013.774366","article-title":"Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides","volume":"13","author":"Dirin","year":"2013","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.addr.2016.01.010_bb0575","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/jps.20051","article-title":"Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate","volume":"93","author":"Raoof","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2016.01.010_bb0580","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1096\/fj.02-0609com","article-title":"The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis","volume":"17","author":"Brenner","year":"2003","journal-title":"FASEB J."},{"key":"10.1016\/j.addr.2016.01.010_bb0585","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1196\/annals.1405.022","article-title":"Antisense treatment for myasthenia gravis: experience with monarsen","volume":"1132","author":"Sussman","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.addr.2016.01.010_bb0590","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/DDDT.S25716","article-title":"New treatments for myasthenia: a focus on antisense oligonucleotides","volume":"7","author":"Angelini","year":"2013","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.addr.2016.01.010_bb0595","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1749-6632.2012.06825.x","article-title":"Further developments with antisense treatment for myasthenia gravis","volume":"1275","author":"Sussman","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.addr.2016.01.010_bb0600","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-3659(97)00204-6","article-title":"The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins","volume":"52","author":"Bernkop-Schn\u00fcrch","year":"1998","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2016.01.010_bb0605","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/0016-5085(92)90111-B","article-title":"Mediation of trypsin inhibitor-induced pancreatic hypersecretion by secretin and cholecystokinin in rats","volume":"102","author":"Watanabe","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2016.01.010_bb0610","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/00006676-198703000-00007","article-title":"Effect of synthetic protease inhibitor camostate on pancreatic exocrine function in rats","volume":"2","author":"Otsuki","year":"1987","journal-title":"Pancreas"},{"key":"10.1016\/j.addr.2016.01.010_bb0615","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/0304-4165(76)90294-4","article-title":"Hypertrophy and hyperplasia of the neonatal rat exocrine pancreas induced by orally administered soybean trypsin inhibitor","volume":"421","author":"Melmed","year":"1976","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2016.01.010_bb0620","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1079\/BJN19930126","article-title":"The effect of trypsin inhibitor on the pancreas and small intestine of mice","volume":"70","author":"Ge","year":"1993","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.addr.2016.01.010_bb0625","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0378-5173(95)04134-6","article-title":"The colonic absorption of human calcitonin: the effects of increasing local concentration and co-administration with a protease inhibitor","volume":"126","author":"Hastewell","year":"1995","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2016.01.010_bb0630","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1023\/A:1018968611962","article-title":"Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats","volume":"11","author":"Yamamoto","year":"1994","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2016.01.010_bb0635","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1128\/AAC.36.5.955","article-title":"Dissociation of the antimicrobial activity of bacitracin USP from its renovascular effects","volume":"36","author":"Drapeau","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2016.01.010_bb0640","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/labinvest.3700203","article-title":"Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity","volume":"85","author":"Gibo","year":"2005","journal-title":"Lab. Investig."},{"key":"10.1016\/j.addr.2016.01.010_bb0645","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1124\/jpet.108.148155","article-title":"Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease","volume":"329","author":"Coote","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.addr.2016.01.010_bb0650","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1208\/s12248-011-9307-4","article-title":"Absorption enhancers: applications and advances","volume":"14","author":"Aungst","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2016.01.010_bb0655","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.addr.2009.09.006","article-title":"Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic","volume":"61","author":"Maher","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2016.01.010_bb0660","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.biomaterials.2012.09.051","article-title":"Sodium caprate as an enhancer of macromolecule permeation across tricellular tight junctions of intestinal cells","volume":"34","author":"Krug","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2016.01.010_bb0665","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1248\/bpb.21.615","article-title":"Effectiveness and toxicity screening of various absorption enhancers using Caco-2 cell monolayers","volume":"21","author":"Quan","year":"1998","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.addr.2016.01.010_bb0670","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0928-0987(02)00162-8","article-title":"Effect of sodium caprate on the intestinal absorption of two modified antisense oligonucleotides in pigs","volume":"17","author":"Raoof","year":"2002","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2016.01.010_bb0675","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0378-5173(99)00213-6","article-title":"In vitro and in vivo evaluation of effects of sodium caprate on enteral peptide absorption and on mucosal morphology","volume":"191","author":"Chao","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2016.01.010_bb0680","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1023\/A:1012112219578","article-title":"Mechanism of absorption enhancement in humans after rectal administration of ampicillin in suppositories containing sodium caprate","volume":"14","author":"Lindmark","year":"1997","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2016.01.010_bb0685","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11095-007-9438-6","article-title":"Mechanistic understanding of oral drug absorption enhancement of cromolyn sodium by an amino acid derivative","volume":"25","author":"Alani","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2016.01.010_bb0690","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1177\/1091581809337737","article-title":"Subchronic oral toxicity of salcaprozate sodium (SNAC) in Sprague\u2013Dawley and Wistar rats","volume":"28","author":"Riley","year":"2009","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.addr.2016.01.010_bb0695","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ejps.2005.03.003","article-title":"Investigation of the enhancing mechanism of sodium N-[8-(2-hydroxybenzoyl)amino]caprylate effect on the intestinal permeability of polar molecules utilizing a voltage clamp method","volume":"25","author":"Hess","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2016.01.010_bb0700","first-page":"233","article-title":"Phase I clinical study to select a novel oral formulation for ibandronate containing the excipient sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC)","volume":"67","author":"Bittner","year":"2012","journal-title":"Pharmazie"},{"key":"10.1016\/j.addr.2016.01.010_bb0705","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.clinthera.2011.05.088","article-title":"Pharmacokinetics of oral cyanocobalamin formulated with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC): an open-label, randomized, single-dose, parallel-group study in healthy male subjects","volume":"33","author":"Castelli","year":"2011","journal-title":"Clin. Ther."},{"key":"10.1016\/j.addr.2016.01.010_bb0710","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3945\/ajcn.2010.29663","article-title":"Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects","volume":"92","author":"Steinert","year":"2010","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.addr.2016.01.010_bb0715","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.autrev.2015.01.009","article-title":"Changes in intestinal tight junction permeability associated with industrial food additives explain the rising incidence of autoimmune disease","volume":"14","author":"Lerner","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.addr.2016.01.010_bb0720","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature14232","article-title":"Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome","volume":"519","author":"Chassaing","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.addr.2016.01.010_bb0725","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s12223-010-0057-y","article-title":"PCR-DGGE-based study of fecal microbial stability during the long-term chitosan supplementation of humans","volume":"55","author":"Mr\u00e1zek","year":"2010","journal-title":"Folia Microbiol."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X16300278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X16300278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:35:58Z","timestamp":1759206958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X16300278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":145,"alternative-id":["S0169409X16300278"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2016.01.010","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral delivery of macromolecular drugs: Where we are after almost 100years of attempts","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2016.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}